Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 42-45

  George, Erin M ^a   Herzog, Thomas J ^a   Neugut, Alfred I ^a,b,c   Lu, Yu Shiang ^a   Burke, William M ^a   Lewin, Sharyn N ^a,c   Hershman, Dawn L ^a,b,c   Wright, Jason D ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Department of Medicine   (United States)

^c Department of Medicine   (United States)

Author keywords

Cancer; Carcinosarcoma; Mixed mullerian tumor; Ovarian cancer; Ovarian carcinoma; Surgery

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARIAN CARCINOSARCOMA; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 84885300601     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.034     Document Type: Article

References (29)

1. Siegel R,NaishadhamD, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1): 10-29 [Epub 2012/01/13].
2. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol 2012;125(1):271-7 [Epub 2011/12/14].
3. Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007;17(2):316-24 [Epub 2007/03/17].
4. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, et al. Carcinosarcoma of the ovary. Br J Cancer 2003;88(5):654-7 [Epub 2003/03/06].
5. Barnholtz-Sloan JS, Morris R, Malone Jr JM, Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004;93(2):506-12 [Epub 2004/04/22].
6. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol 1995;6(8):755-8 [Epub 1995/10/01].
7. Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004;100(10):2148-53 [Epub 2004/05/13].
8. Rauh-Hain JA, GrowdonWB, Rodriguez N, Goodman AK, Boruta 2nd DM, Schorge JO, et al. Carcinosarcoma of the ovary: a case-control study.Gynecol Oncol 2011;121(3): 477-81 [Epub 2011/03/23].
9. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol 2002;85(3):459-63 [Epub 2002/06/08].
10. Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, et al. Carcinosarcoma of the ovary-a case series. Gynecol Oncol 2006;100(1):128-32 [Epub 2005/10/11].
11. Sutton GP, Blessing JA, Homesley HD, Malfetano JH. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 1994;53(1):24-6 [Epub 1994/04/01].
12. Tate Thigpen J, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 2004;93(2):336-9 [Epub 2004/04/22].
13. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31(8): 732-48.
14. Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 2011;205(5):480 [e1-8. Epub 2011/08/25].
15. Wethington SL, Herzog TJ, Seshan VE, Bansal N, Schiff PB, BurkeWM, et al. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer. Cancer 2008;113(12):3298-306 [Epub 2008/11/14].
16. Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27(8):1214-9 [Epub 2009/01/28].
17. Wright JD, ShahM,MathewL, BurkeWM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009;115(18): 4118-26 [Epub 2009/08/12].
18. Surveillance, Exidemiology, and End Results, National Cancer Institute, DCCPS. Surveillance Research Program, Surveillance Systems Branch. released April 2012, based on the November 2011 submission http://.seer.cancer.gov.
19. Spoozak L, Lewin SN, Burke WM, Deutsch I, Sun X, Herzog TJ, et al. Microinvasive adenocarcinoma of the cervix. Am J Obstet Gynecol 2012;206(1):80 [e1-6. Epub 2011/09/24].
20. Wright JD, NathavithArana R, Lewin SN, Sun X, Deutsch I, Burke WM, et al. Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access. Obstet Gynecol 2010;115(3):585-90 [Epub 2010/02/24].
21. Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998;82(9):1731-7 [Epub 1998/05/12].
22. Muntz HG, Jones MA, Goff BA, Fuller Jr AF, Nikrui N, Rice LW, et al. Malignant mixed mullerian tumors of the ovary: experiencewith surgical cytoreduction and combination chemotherapy. Cancer 1995;76(7):1209-13 [Epub 1995/10/01].
23. Inthasorn P, Beale P, Dalrymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol 2003;43(1):61-4 [Epub 2003/05/21].
24. MorrowCP, Bundy BN, Hoffman J, Sutton G, Homesley H. Adriamycin chemotherapy formalignantmixedmesodermal tumor of the ovary. A Gynecologic OncologyGroup Study. Am J Clin Oncol 1986;9(1):24-6 [Epub 1986/02/01].
25. Hellstrom AC, Tegerstedt G, Silfversward C, Pettersson F. Malignant mixed mullerian tumors of the ovary: histopathologic and clinical review of 36 cases. Int J Gynecol Cancer 1999;9(4):312-6 [Epub 2001/03/10].
26. Loizzi V, Cormio G, Camporeale A, FalagarioM, DeMitri P, Scardigno D, et al. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology 2011;80(1-2):102-6 [Epub 2011/06/17].
27. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, et al. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008;108(1):136-40 [Epub 2007/10/16].
28. Bilodeau L, Preese LM, Apple FS. Does low total creatine kinase rule out myocardial infarction? Ann Intern Med 1992;116(6):523-4 [Epub 1992/03/15].
29. Silasi DA, Illuzzi JL, Kelly MG, Rutherford TJ, Mor G, Azodi M, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008;18(1):22-9 [Epub 2007/04/25].